Walvax Biotechnology Co Ltd
Walvax Biotechnology Co Ltd is a Chinese biotechnology company that develops, produces, and sells vaccines and other biopharmaceutical products, primarily in the domestic market.
Business. Walvax Biotechnology Co Ltd (300142.SZ) is a pharmaceutical company engaged in the research, development, and sale of vaccines and other biological products. The firm is headquartered in China and is primarily listed on the Shenzhen Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.
Analyst recommendations
1 analysts · consensus SellAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Walvax Biotechnology Co Ltd (300142.SZ) is a pharmaceutical company engaged in the research, development, and sale of vaccines and other biological products. The firm is headquartered in China and is primarily listed on the Shenzhen Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.
The company maintains a strong liquidity position with a current ratio of 2.35, indicating sufficient short-term assets to cover liabilities. However, its free cash flow is negative at -4.1 million CNY, suggesting that operating cash flow is being consumed by capital expenditures. The debt-to-equity ratio is low at 0.05, reflecting a conservative capital structure.
Profitability metrics show a return on equity (ROE) of 2.06% and a return on assets (ROA) of 1.47%, both below the typical thresholds for pharmaceutical firms. The gross margin is 73.9%, which is strong, but the operating margin is only 7.7%, indicating high operating expenses relative to revenue.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regulatory and market risks in China. No material revenue is attributed to international markets.
Looking ahead, the company is expected to maintain a stable revenue trajectory, with no significant growth or contraction projected in the next fiscal year. The capital expenditure of -509.5 million CNY suggests ongoing investment in production capacity, but the free cash flow remains negative.
The risk assessment highlights a medium liquidity risk due to negative net cash after subtracting total debt. The dilution risk is low, with no near-term pressure from share issuance. However, the high price-to-earnings ratio of 125.34 and price-to-book ratio of 2.58 suggest that the stock is currently overvalued relative to its fundamentals.
Recent investor relations data shows a mean price target of 8.00 CNY, significantly below the current market price of 13.93 CNY. Analysts have not issued any strong buy, buy, or hold recommendations, indicating a neutral to bearish sentiment.
- The company has a strong current ratio but negative free cash flow, indicating potential liquidity constraints.
- ROE and ROA are below industry norms, suggesting suboptimal capital efficiency.
- Revenue is concentrated in a single segment and domestic market, increasing regulatory and market risks.
- Analysts have issued a mean price target significantly below the current market price, indicating a bearish outlook.
- The stock is overvalued based on high P/E and P/B ratios.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,18 |
| Revenue | —no estimate | —no estimate | 2,5B CNY |
| Operating income | —no estimate | —no estimate | 280,5M CNY |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Walvax Biotechnology Co Ltd Market data — financials · 2026-05-26
- Walvax Biotechnology Co Ltd Market data — analyst estimates · 2026-05-26
- Walvax Biotechnology Co Ltd Market data — ESG · 2026-05-26
Ownership & reference
Leadership
- Runsheng JiangPresident, Director
- Wei YaoPresident, Director